Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Florida
MedSIR
Royal Marsden NHS Foundation Trust
Dana-Farber Cancer Institute
University of Florida
Essen Biotech
Royal Marsden NHS Foundation Trust
Memorial Sloan Kettering Cancer Center
Centre Leon Berard
St. Jude Children's Research Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Jazz Pharmaceuticals
Haihe Biopharma Co., Ltd.
University of Iowa
St. Jude Children's Research Hospital
Perspective Therapeutics
M.D. Anderson Cancer Center
Institut Bergonié
Ocellaris Pharma, Inc.
Eli Lilly and Company
Swiss Cancer Institute
Hoffmann-La Roche
Tanabe Pharma America, Inc.
Massachusetts General Hospital
Eli Lilly and Company
National Taiwan University Hospital
Transgene
Turning Point Therapeutics, Inc.
Tango Therapeutics, Inc.
Dana-Farber Cancer Institute
Hadassah Medical Organization
Lantheus Medical Imaging
Essen Biotech
Turning Point Therapeutics, Inc.
PharmaMar
Cancer Research UK
ImmunoGenesis
Hutchmed
Columbia University